How to appeal a Humana rare disease — ert, substrate reduction, gene therapy denial
42 CFR Part 422 Subpart M (Medicare Advantage) · 60-day window · 30-day decision
To appeal a Humana rare disease — ert, substrate reduction, gene therapy denial, file an internal appeal within 60 days of the date on the denial letter through Humana's member or provider portal, under 42 CFR Part 422 Subpart M (Medicare Advantage). Humana returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).
Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
What Humana's policy requires for rare disease — ert, substrate reduction, gene therapy
Cited policy: Humana MA — buy-and-bill J-codes (Part B) + Part D for oral SRT
MA must comply with Medicare NCDs/LCDs and 42 USC §1395x(t)(2). Oncology Part B drugs follow 'reasonable and necessary' + compendium standard.
How Humana denies rare disease — ert, substrate reduction, gene therapy — and how to counter it
Where Humana pushes back: 1) Part B vs Part D coverage confusion (oral SRT denied under medical, IV ERT denied under pharmacy); 2) ASP+6% reimbursement disputes with infusion sites; 3) MA Part B step therapy under CMS 2019 rule.
Counter-arguments that hold up: Cite Medicare Benefit Policy Manual Ch. 15 §50 for incident-to physician-administered drugs (Part B). 42 USC §1395x(t)(2) off-label compendium statute (DRUGDEX/AHFS, NOT NCCN for non-oncology). For MA step therapy: cite CMS appeal rights and continuity rule — step therapy cannot be applied to enrollees already stable on therapy.
What Humana typically denies for rare disease — ert, substrate reduction, gene therapy
Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For rare disease — ert, substrate reduction, gene therapy, expect:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Treatments most often denied in this category
These are the rare disease — ert, substrate reduction, gene therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Pompe ERT
- Fabry ERT
- Galafold (Fabry SRT)
- Gaucher ERT
- Gaucher SRT
- MPS I ERT
How to submit the appeal to Humana
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
- File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Humana rare disease — ert, substrate reduction, gene therapy denial?
Humana allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Humana appeal?
Members can submit through the Humana member portal at https://www.humana.com. Providers should use the provider portal at https://www.humana.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Humana most often issue for rare disease — ert, substrate reduction, gene therapy?
For rare disease — ert, substrate reduction, gene therapy, Humana most often denies on: 1) Part B vs Part D coverage confusion (oral SRT denied under medical, IV ERT denied under pharmacy); 2) ASP+6% reimbursement disputes with infusion sites; 3) MA Part B step therapy under CMS 2019 rule. The strongest counters: Cite Medicare Benefit Policy Manual Ch. 15 §50 for incident-to physician-administered drugs (Part B). 42 USC §1395x(t)(2) off-label compendium statute (DRUGDEX/AHFS, NOT NCCN for non-oncology). For MA step therapy: cite CMS appeal rights and continuity rule — step therapy cannot be applied to enrollees already stable on therapy.
What if Humana denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
- Humana glp-1 weight-loss drugs denial
- Humana mental health & behavioral health denial
- Humana fertility & ivf denial
- Humana adult adhd medications denial
- UnitedHealthcare rare disease — ert, substrate reduction, gene therapy denial
- Elevance Health rare disease — ert, substrate reduction, gene therapy denial
- Aetna rare disease — ert, substrate reduction, gene therapy denial
Start your Rare disease — ERT, substrate reduction, gene therapy appeal
Upload your Humana denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to 42 CFR Part 422 Subpart M (Medicare Advantage).
Get started →Contact: hello@denialhelp.com